MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial ...
Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (ANTX), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results